E
Lyell Immunopharma, Inc. LYEL
$0.5854 -$0.0209-3.45%
Recommendation
Sell
Prev Close
$0.6063
Volume
1,017,265
Avg Vol (90D)
1,217,783
Market Cap
$179.00M
Dividend & Yield
--
52-Week Range
$0.5092 - $3.15
P/E (TTM)
--
EPS (TTM)
-$1.28
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Lyell Immunopharma (NASDAQ:LYEL) Receives Neutral Rating from HC Wainwright
3/14/2025 - MarketBeat
Analysts Conflicted on These Healthcare Names: Electrocore (ECOR), Viking Therapeutics (VKTX) and Lyell Immunopharma (LYEL)
3/13/2025 - TipRanks Financial Blog
Lyell Immunopharma's Global Expansion Strategy: Navigating Risks and Challenges
3/13/2025 - TipRanks Financial Blog
Lyell Immunopharma (NASDAQ:LYEL) Issues Quarterly Earnings Results
3/12/2025 - MarketBeat
Lyell Immunopharma reports Q4 results
3/11/2025 - SeekingAlpha.com: All News
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and ...
3/11/2025 - GuruFocus
Lyell Immunopharma reports Q4 net loss $45.9M vs. net loss $44M last year
3/11/2025 - TipRanks Financial Blog
Lyell Immunopharma reports Q4 net loss $45.9M vs. net loss $44M last year
3/11/2025 - The Fly
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
3/11/2025 - Globe Newswire
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Down 16.3% in February
3/6/2025 - MarketBeat
Commit To Purchase Lyell Immunopharma Inc At $0.50, Earn 24.8% Annualized Using Options
2/21/2025 - Stock Options Channel
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
2/18/2025 - GuruFocus
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
2/18/2025 - Globe Newswire
Following a 67% decline over last year, recent gains may please Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners
2/17/2025 - Simply Wall St
BlackRock, Inc. Reduces Stake in Lyell Immunopharma Inc
2/5/2025 - GuruFocus
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why
1/22/2025 - Zacks Investment Research
Seattle biotech startup Tune Therapeutics lands $175M to support clinical research
1/13/2025 - GeekWire
Lyell Immunopharma price target lowered to 60c from $1 at BofA
1/12/2025 - TipRanks Financial Blog
Lyell Immunopharma price target lowered by 40c at BofA, here's why
1/12/2025 - The Fly
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)
1/11/2025 - TipRanks Financial Blog
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
1/9/2025 - Globe Newswire
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
12/31/2024 - Zacks Investment Research
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
12/30/2024 - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)
12/24/2024 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$61.00K
EBITDA (TTM)
-$199.72M
EBIT (TTM)
-$219.35M
Net Income (TTM)
-$342.99M
Balance Sheet
Total Assets (Q)
$490.86M
Total Debt (Q)
$58.97M
Total Liabilities (Q)
$108.04M
Book Value Per Share (Q)
$1.30
Cash Flow
Cash from Operations (TTM)
-$162.39M
Cash from Investing (TTM)
$122.42M
Cash from Financing (TTM)
$1.33M
Net Change in Cash (TTM)
-$38.64M
Filings
Filing Date
Tuesday, March 11, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
2.12
7-Day Total Return
-16.37%
30-Day Total Return
0.38%
60-Day Total Return
-13.12%
90-Day Total Return
-39.04%
Year to Date Total Return
-9.24%
1-Year Total Return
-73.51%
2-Year Total Return
-75.09%
3-Year Total Return
-89.58%
5-Year Total Return
--
52-week Low
Feb 11, 2025 - $0.5092
52-week High
Apr 12, 2024 - $3.15
Valuation
Market Cap
$179.00M - Micro Cap
Enterprise Value
-$145.58M
Price/Sales (TTM)
3,031.50
Price/Book (Q)
0.47
Dividends and Shares
Shares Outstanding
279.95M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.lyell.com
Phone Number
(650) 695-0677
Address
201 Haskins Way
South San Francisco, CA 94080
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors... more
NASDAQ 03/14/2025 4:00PM Eastern Quotes delayed
Weiss Ratings